Suppr超能文献

纤维肌痛的疼痛管理:当前与未来的选择

Managing Pain in Fibromyalgia: Current and Future Options.

作者信息

Clarke Hance, Peer Miki, Miles Sarah, Fitzcharles Mary-Ann

机构信息

Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Canada.

Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, Toronto, Canada.

出版信息

Drugs. 2025 Jul 18. doi: 10.1007/s40265-025-02204-x.

Abstract

Pain relief is a key element of fibromyalgia (FM) treatment. Current guidelines recommend antidepressant (i.e. serotonin-norepinephrine reuptake inhibitors) and anticonvulsant medications (gabapentin/pregabalin), drugs that provide only modest relief, with limitations primarily driven by side effects. In contrast, traditional analgesic drugs, although not sufficiently tested in FM, are commonly used by patients. This dearth of effective treatments has led to isolated, mostly small studies of less familiar drug treatments for FM-related pain. Although no single drug has emerged with appreciable effect, some agents such as cannabinoids and naltrexone, amongst others, have shown some pain modulatory effects. In the absence of drugs in the pipeline, non-pharmacological interventions such as behavioural interventions, neuromodulation techniques and faecal transplantation have been studied. This narrative review will focus on drugs and interventions that have been examined in recent years to modulate pain in FM.

摘要

疼痛缓解是纤维肌痛(FM)治疗的关键要素。当前指南推荐使用抗抑郁药(即5-羟色胺-去甲肾上腺素再摄取抑制剂)和抗惊厥药物(加巴喷丁/普瑞巴林),这些药物只能提供适度缓解,其局限性主要由副作用所致。相比之下,传统镇痛药虽未在纤维肌痛中得到充分测试,但患者却普遍使用。有效治疗方法的匮乏促使人们对纤维肌痛相关疼痛的不太常用药物治疗进行了一些孤立的、大多规模较小的研究。尽管尚未出现具有显著疗效的单一药物,但一些药物如大麻素和纳曲酮等已显示出一定的疼痛调节作用。由于没有正在研发的药物,人们对行为干预、神经调节技术和粪便移植等非药物干预措施进行了研究。本叙述性综述将聚焦于近年来已研究的用于调节纤维肌痛疼痛的药物和干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验